|
1
|
Jemal A, Siegel R, Ward E, Hao Y, Xu J and
Thun MJ: Cancer statistics, 2009. CA Cancer J Clin. 59:225–249.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Eccles MR, He S, Legge M, Kumar R, Fox J,
Zhou C, French M and Tsai RW: PAX genes in development and disease:
The role of PAX2 in urogenital tract development. Int J Dev Biol.
46:535–544. 2002.PubMed/NCBI
|
|
3
|
Lang D, Powell SK, Plummer RS, Young KP
and Ruggeri BA: PAX genes: Roles in development, pathophysiology,
and cancer. Biochem Pharmacol. 73:1–14. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Gnarra JR and Dressler GR: Expression of
Pax-2 in human renal cell carcinoma and growth nhibition by
antisense oligonucleotides. Cancer Res. 55:4092–4098.
1995.PubMed/NCBI
|
|
5
|
Silberstein GB, Dressler GR and Van Horn
K: Expression of the PAX2 oncogene in human breast cancer and its
role in progesterone-dependent mammary growth. Oncogene.
21:1009–1016. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Tung CS, Mok SC, Tsang YT, Zu Z, Song H,
Liu J, Deavers MT, Malpica A, Wolf JK, Lu KH, et al: PAX2
expression in low malignant potential ovarian tumors and low-grade
ovarian serous carcinomas. Mod Pathol. 22:1243–1250. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Beauchemin D, Lacombe C and Van Themsche
C: PAX2 is activated by estradiol in breast cancer cells of the
luminal subgroup selectively, to confer a low invasive phenotype.
Mol Cancer. 10:1482011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wu H, Chen Y, Liang J, Shi B, Wu G, Zhang
Y, Wang D, Li R, Yi X, Zhang H, et al: Hypomethylation-linked
activation of PAX2 mediates tamoxifen-stimulated endometrial
carcinogenesis. Nature. 438:981–987. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wang M, Ma H, Pan Y, Xiao W, Li J, Yu J
and He J: PAX2 and PAX8 reliably distinguishes ovarian serous
tumors from mucinous tumors. Appl Immunohistochem Mol Morphol.
23:280–287. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Gao FF, Krasinskas AM and Chivukula M: Is
PAX2 a reliable marker in differentiating diffuse malignant
mesotheliomas of peritoneum from serous carcinomas of müllerian
origin? Appl Immunohistochem Mol Morphol. 20:272–276. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Tong GX, Chiriboga L, Hamele-Bena D and
Borczuk AC: Expression of PAX2 in papillary serous carcinoma of the
ovary: Immunohistochemical evidence of fallopian tube or secondary
Müllerian system origin? Mod Pathol. 20:856–863. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
O'Donnell AJ, Macleod KG, Burns DJ, Smyth
JF and Langdon SP: Estrogen receptor-alpha mediates gene expression
changes and growth response in ovarian cancer cells exposed to
estrogen. Endocr Relat Cancer. 12:851–866. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hu Z, Zhu L, Tan M, Cai M, Deng L, Yu G,
Liu D, Liu J and Lin B: The expression and correlation between the
transcription factor FOXP1 and estrogen receptors in epithelial
ovarian cancer. Biochimie. 109:42–48. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Cunat S, Hoffmann P and Pujol P: Estrogens
and epithelial ovarian cancer. Gynecol Oncol. 94:25–32. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hurtado A, Holmes KA, Geistlinger TR,
Hutcheson IR, Nicholson RI, Brown M, Jiang J, Howat WJ, Ali S and
Carroll JS: Regulation of ERBB2 by oestrogen receptor-PAX2
determines response to tamoxifen. Nature. 456:663–666. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Machado F, Rodríguez JR, León JP,
Rodríguez JR, Parrilla JJ and Abad L: Tamoxifen and endometrial
cancer. Is screening necessary? A review of the literature. Eur J
Gynaecol Oncol. 26:257–265. 2005.PubMed/NCBI
|
